GlassScriptPhysician profile
John W Rodgers
NPI 1588641112
$18,362.07
in general payments reported to CMS, 2019-2025
63 companies · $2,247 in 2025
The $2,247 reported for 2025 was more than what 78% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,240 · 2020: $3,297 · 2021: $2,623 · 2022: $2,832 · 2023: $2,064 · 2024: $2,059 · 2025: $2,247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,359 · Education: $11.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,358.51 |
| Education | $11.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $4,765.23 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $2,027.71 | 2019-2025 | Breztri, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,419.08 | 2019-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Novo Nordisk INC | $1,091.58 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $792.08 | 2019-2024 | Mounjaro, Zepbound, Jardiance |
| Mallinckrodt Hospital Products INC. | $670.78 | 2020-2024 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $655.95 | 2019-2025 | Glassia, Hyqvia, Cuvitru |
| Genzyme Corporation | $612.14 | 2019-2025 | |
| Abbvie INC. | $530.85 | 2021-2025 | Emblaveo |
| Genentech USA, INC. | $517.71 | 2019-2022 | |
| Amgen INC. | $451.50 | 2020-2025 | Repatha, Repatha, Otezla |
| Janssen Pharmaceuticals, INC | $373.41 | 2019-2022 | |
| Pfizer INC. | $372.77 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $360.50 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $286.83 | 2019-2024 | Dupixent |
Show all 63 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Rodgers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.